Cardiol Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cardiol Therapeutics's earnings have been declining at an average annual rate of -14.6%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 16.4% per year.
Key information
-14.6%
Earnings growth rate
14.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 16.4% |
| Return on equity | -99.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?
May 01
Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?
Jan 06Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?
Sep 13We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully
May 24We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth
Jan 20We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth
Aug 10We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn
Apr 17Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Dec 09We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully
Aug 19Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Apr 18Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth
Jan 03Revenue & Expenses BreakdownBeta
How Cardiol Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -28 | 16 | 14 |
| 30 Sep 23 | 0 | -28 | 15 | 16 |
| 30 Jun 23 | 0 | -30 | 18 | 18 |
| 31 Mar 23 | 0 | -29 | 20 | 19 |
| 31 Dec 22 | 0 | -31 | 22 | 19 |
| 30 Sep 22 | 0 | -30 | 28 | 17 |
| 30 Jun 22 | 0 | -32 | 28 | 14 |
| 31 Mar 22 | 0 | -32 | 28 | 12 |
| 31 Dec 21 | 0 | -32 | 28 | 11 |
| 30 Sep 21 | 0 | -35 | 21 | 15 |
| 30 Jun 21 | 0 | -30 | 16 | 14 |
| 31 Mar 21 | 0 | -27 | 14 | 13 |
| 31 Dec 20 | 0 | -21 | 10 | 11 |
| 30 Sep 20 | 0 | -14 | 10 | 4 |
| 30 Jun 20 | 0 | -13 | 9 | 4 |
| 31 Mar 20 | 0 | -13 | 8 | 4 |
| 31 Dec 19 | 0 | -14 | 8 | 4 |
| 30 Sep 19 | 0 | -20 | 8 | 3 |
| 30 Jun 19 | 0 | -21 | 9 | 2 |
| 31 Mar 19 | 0 | -19 | 7 | 2 |
| 31 Dec 18 | 0 | -16 | 5 | 2 |
| 30 Sep 18 | 0 | -8 | 3 | 1 |
| 30 Jun 18 | 0 | -3 | 2 | 1 |
Quality Earnings: CRDL is currently unprofitable.
Growing Profit Margin: CRDL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRDL is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare CRDL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRDL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: CRDL has a negative Return on Equity (-99.58%), as it is currently unprofitable.